World’s First Clinical Trial for anti-Abeta Vaccine Targeting Alzheimer’s Disease-like Characteristics in People with Down Syndrome

Categories: Blog, Clinical Trials, Ds / Alzheimer's Connection, Ds Research, News
PRESS RELEASE – Issued by AC Immune Studies AC Immune’s ACI-24, the first anti-amyloid vaccine for treatment of Alzheimer’s disease-like characteristics in people with Down syndrome Clinical Study is done in collaboration with University of California San Diego US NIH provides significant funding with an additional grant from the LuMind Research Down Syndrome Foundation Alzheimer’s …

Read More

A Research Story: Fragile X

Categories: Blog, Clinical Trials

On National Public Radio, there was a story about a foundation started by concerned parents, funding impressive discoveries, results of clinical trials, and the quest for new avenues of research. Nope, not the LuMind Foundation (or even our former name Down Syndrome Research and Treatment Foundation). This is a story about fragile X. The NPR piece, ‘A Family’s …

Read More

Update on Transition Clinical Trial: ELND005

Categories: Blog, Clinical Trials, Ds Research, News

Transition Therapeutics Inc. (Elan) announced the results of a clinical study of drug candidate ELND005 in young adults with Down syndrome. The study focuses on neuropsychiatric symptoms associated with Alzheimer’s disease and cognition in people with Ds. In our September 2013 Newsflash, LuMind Foundation’s Chief Scientific Officer Dr. Harpold explained the ELND005 study. Essentially, ELND005 …

Read More

Clinical Trials UPDATE: Roche Initiates RG1662 Phase II Clinical Trials for Individuals with Down syndrome

Categories: Blog, Clinical Trials, Ds Research

LuMind Foundation-supported research has led to clinical trials currently in progress to address developmental cognitive deficits and those impairments associated with Alzheimer’s disease. Roche, a leader in innovative research-focused healthcare and the world’s largest biotech company, has initiated a new multi-national Phase II clinical trial to evaluate the efficacy and safety of RG1662 in adolescents and adults, …

Read More